Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Lung Cancer

  Free Subscription

Articles published in Lancet

Retrieve available abstracts of 19 articles:
HTML format

Single Articles

    May 2020
  1. HARRIS DA, Willis J, Tomann M
    A new era of coal workers' pneumoconiosis: decades in mines may not be required.
    Lancet. 2020;395:e82.

    November 2019
  2. LUDMIR EB, McCaw ZR, Grossberg AJ, Wei LJ, et al
    Quantifying the benefit of non-small-cell lung cancer immunotherapy.
    Lancet. 2019;394:1904.

  3. MOK TSK, Zhang J, Lopes G
    Quantifying the benefit of non-small-cell lung cancer immunotherapy - Authors' reply.
    Lancet. 2019;394:1904-1905.

    Lung cancer: some progress, but still a lot more to do.
    Lancet. 2019;394:1880.

    October 2019
  5. PAZ-ARES L, Dvorkin M, Chen Y, Reinmuth N, et al
    Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
    Lancet. 2019 Oct 4. pii: S0140-6736(19)32222.
    PubMed     Abstract available

    Immunotherapy: a new era in small-cell lung cancer.
    Lancet. 2019 Oct 4. pii: S0140-6736(19)32235.

    September 2019
  7. ZHOU M, Wang H, Zeng X, Yin P, et al
    Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
    Lancet. 2019;394:1145-1158.
    PubMed     Abstract available

    May 2019
  8. LOO BW JR, Diehn M
    SABR-COMET: harbinger of a new cancer treatment paradigm.
    Lancet. 2019;393:2013-2014.

  9. SMIT EF, de Langen AJ
    Pembrolizumab for all PD-L1-positive NSCLC.
    Lancet. 2019;393:1776-1778.

    April 2019
  10. MOK TSK, Wu YL, Kudaba I, Kowalski DM, et al
    Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
    Lancet. 2019 Apr 4. pii: S0140-6736(18)32409.
    PubMed     Abstract available

    September 2017
    Lung cancer.
    Lancet. 2017;390:928.

    August 2017
  12. RIDKER PM, MacFadyen JG, Thuren T, Everett BM, et al
    Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
    Lancet. 2017 Aug 25. pii: S0140-6736(17)32247.
    PubMed     Abstract available

    Potential efficacy of interleukin-1beta inhibition in lung cancer.
    Lancet. 2017 Aug 25. pii: S0140-6736(17)32289.

    May 2017
  14. ROSS RJ, Mann NC
    Synchronous distal phalangeal metastases from primary non-small-cell lung cancer.
    Lancet. 2017 May 25. pii: S0140-6736(17)31288.

  15. HIDA T, Nokihara H, Kondo M, Kim YH, et al
    Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
    Lancet. 2017 May 10. pii: S0140-6736(17)30565.
    PubMed     Abstract available

  16. GAINOR JF, Shaw AT
    J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer.
    Lancet. 2017 May 10. pii: S0140-6736(17)31074.

    April 2017
  17. LANGLEY RE, Nankivell M, Barton R, Faivre-Finn C, et al
    Whole brain radiotherapy for non-small cell lung cancer - Authors' reply.
    Lancet. 2017;389:1395-1396.

  18. ZHU J, Kang M, Fan X
    Whole brain radiotherapy for non-small cell lung cancer.
    Lancet. 2017;389:1395.

  19. CAGNEY DN, Alexander BM, Aizer AA
    Whole brain radiotherapy for non-small cell lung cancer.
    Lancet. 2017;389:1394-1395.

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.